AAAAAA

   
Results: 1-24 |
Results: 24
AN AUTOMATED CHROMOGENIC PEPTIDE SUBSTRATE ASSAY FOR COAGULATION-FACTOR-XII
Authors: JONES DW GALLIMORE MJ WINTER M
Citation: Dw. Jones et al., AN AUTOMATED CHROMOGENIC PEPTIDE SUBSTRATE ASSAY FOR COAGULATION-FACTOR-XII, Blood coagulation & fibrinolysis, 9(2), 1998, pp. 183-187
FACTOR-XII DETERMINATIONS IN THE PRESENCE AND ABSENCE OF PHOSPHOLIPIDANTIBODIES
Authors: GALLIMORE MJ JONES DW WINTER M
Citation: Mj. Gallimore et al., FACTOR-XII DETERMINATIONS IN THE PRESENCE AND ABSENCE OF PHOSPHOLIPIDANTIBODIES, Thrombosis and haemostasis, 79(1), 1998, pp. 87-90
FACTOR-XII ANTIBODIES IN LUPUS ANTICOAGULANT POSITIVE PATIENTS
Authors: JONES DW HARRIS S GALLIMORE MJ WINTER M
Citation: Dw. Jones et al., FACTOR-XII ANTIBODIES IN LUPUS ANTICOAGULANT POSITIVE PATIENTS, British Journal of Haematology, 101, 1998, pp. 218-218
FACTOR-XII DETERMINATIONS AND LUPUS ANTICOAGULANTS
Authors: JONES DW GALLIMORE MJ WINTER M
Citation: Dw. Jones et al., FACTOR-XII DETERMINATIONS AND LUPUS ANTICOAGULANTS, Blood coagulation & fibrinolysis, 8(8), 1997, pp. 531-532
CONTACT FACTOR ASSAYS AND STANDARDIZATION
Authors: JONES DW GALLIMORE MJ WINTER M
Citation: Dw. Jones et al., CONTACT FACTOR ASSAYS AND STANDARDIZATION, Thrombosis and haemostasis, 1997, pp. 855-855
THE INCIDENCE OF FACTOR-XII DEFICIENCY IN A POPULATION OF BLOOD-DONORS
Authors: JONES DW GALLIMORE MJ HARRIS S WINTER M GRANT D MACKIE I MACHIN S
Citation: Dw. Jones et al., THE INCIDENCE OF FACTOR-XII DEFICIENCY IN A POPULATION OF BLOOD-DONORS, Thrombosis and haemostasis, 1997, pp. 860-860
THE INCIDENCE OF PSEUDO FXII DEFICIENCY IN LUPUS ANTICOAGULANT POSITIVE PATIENTS
Authors: GALLIMORE MJ JONES DW WINTER M
Citation: Mj. Gallimore et al., THE INCIDENCE OF PSEUDO FXII DEFICIENCY IN LUPUS ANTICOAGULANT POSITIVE PATIENTS, Thrombosis and haemostasis, 1997, pp. 2187-2187
PSEUDO FACTOR-XII DEFICIENCY AND PHOSPHOLIPID ANTIBODIES
Authors: JONES DW GALLIMORE MJ WINTER M
Citation: Dw. Jones et al., PSEUDO FACTOR-XII DEFICIENCY AND PHOSPHOLIPID ANTIBODIES, Thrombosis and haemostasis, 75(4), 1996, pp. 696-697
INFLUENCE OF HEPARIN, HEPARIN PLUS APROTININ AND HIRUDIN ON CONTACT ACTIVATION IN A CARDIOPULMONARY BYPASS MODEL
Authors: WENDEL HP HELLER W GALLIMORE MJ
Citation: Hp. Wendel et al., INFLUENCE OF HEPARIN, HEPARIN PLUS APROTININ AND HIRUDIN ON CONTACT ACTIVATION IN A CARDIOPULMONARY BYPASS MODEL, Immunopharmacology, 32(1-3), 1996, pp. 57-61
HEPARIN-COATED DEVICES AND HIGH-DOSE APROTININ OPTIMALLY INHIBIT CONTACT SYSTEM ACTIVATION IN AN IN-VITRO CARDIOPULMONARY BYPASS MODEL
Authors: WENDEL HP HELLER W GALLIMORE MJ
Citation: Hp. Wendel et al., HEPARIN-COATED DEVICES AND HIGH-DOSE APROTININ OPTIMALLY INHIBIT CONTACT SYSTEM ACTIVATION IN AN IN-VITRO CARDIOPULMONARY BYPASS MODEL, Immunopharmacology, 32(1-3), 1996, pp. 128-130
HETEROZYGOUS FACTOR-XII DEFICIENCY WITHIN A GROUP OF BLOOD-DONORS IN KENT
Authors: JONES DW GALLIMORE MJ WINTER M COHEN H MACKIE I MACHIN S
Citation: Dw. Jones et al., HETEROZYGOUS FACTOR-XII DEFICIENCY WITHIN A GROUP OF BLOOD-DONORS IN KENT, British Journal of Haematology, 93, 1996, pp. 127-127
DISCREPANCY BETWEEN CLOTTING, CHROMOGENIC SUBSTRATE AND IMMUNOLOGICALASSAYS FOR FACTOR-XII IN LUPUS ANTICOAGULANT POSITIVE PATIENTS
Authors: JONES DW GALLIMORE MJ WINTER M
Citation: Dw. Jones et al., DISCREPANCY BETWEEN CLOTTING, CHROMOGENIC SUBSTRATE AND IMMUNOLOGICALASSAYS FOR FACTOR-XII IN LUPUS ANTICOAGULANT POSITIVE PATIENTS, British Journal of Haematology, 93, 1996, pp. 342-342
ENZYME-ACTIVITY OTHER THAN FACTOR IXA IN FACTOR-IX CONCENTRATES
Authors: JONES DW WINTER M GALLIMORE MJ
Citation: Dw. Jones et al., ENZYME-ACTIVITY OTHER THAN FACTOR IXA IN FACTOR-IX CONCENTRATES, British Journal of Haematology, 93, 1996, pp. 343-343
LYMPHOCYTE DYSFUNCTION RELATED TO AMIDOLYTIC ACTIVITY OF FACTOR-VIII CONCENTRATES
Authors: HAY CRM MCKERNAN AM MCEVOY P JONES DW GALLIMORE MJ
Citation: Crm. Hay et al., LYMPHOCYTE DYSFUNCTION RELATED TO AMIDOLYTIC ACTIVITY OF FACTOR-VIII CONCENTRATES, Thrombosis and haemostasis, 73(6), 1995, pp. 1017-1017
APROTININ ADDS BENEFICIAL-EFFECTS TO HEPARIN-COATED DEVICES REGARDS BLOOD-CELLS AND CONTACT SYSTEM ACTIVATION IN AN IN-VITRO CARDIOPULMONARY BYPASS MODEL
Authors: WENDEL HP HELLER W SCHULZE HJ GALLIMORE MJ
Citation: Hp. Wendel et al., APROTININ ADDS BENEFICIAL-EFFECTS TO HEPARIN-COATED DEVICES REGARDS BLOOD-CELLS AND CONTACT SYSTEM ACTIVATION IN AN IN-VITRO CARDIOPULMONARY BYPASS MODEL, Thrombosis and haemostasis, 73(6), 1995, pp. 1346-1346
RAISED ELASTASE ALPHA-1-PROTEINASE INHIBITOR COMPLEX LEVELS IN PATIENTS WITH HIV-INFECTION
Authors: JONES DW WINTER M GALLIMORE MJ MASON C
Citation: Dw. Jones et al., RAISED ELASTASE ALPHA-1-PROTEINASE INHIBITOR COMPLEX LEVELS IN PATIENTS WITH HIV-INFECTION, Thrombosis and haemostasis, 73(6), 1995, pp. 1393-1393
HETEROZYGOUS FACTOR-XII DEFICIENCY AND THROMBOTIC RISK
Authors: WINTER M JONES DW GALLIMORE MJ
Citation: M. Winter et al., HETEROZYGOUS FACTOR-XII DEFICIENCY AND THROMBOTIC RISK, Thrombosis and haemostasis, 73(6), 1995, pp. 1407-1407
EVIDENCE FOR CONTACT SYSTEM ACTIVATION IN PATIENTS INFECTED WITH HIV
Authors: JONES DW WINTER M GALLIMORE MJ MASON C
Citation: Dw. Jones et al., EVIDENCE FOR CONTACT SYSTEM ACTIVATION IN PATIENTS INFECTED WITH HIV, Thrombosis and haemostasis, 73(6), 1995, pp. 1410-1410
HEPARIN-COATED OXYGENATORS SIGNIFICANTLY REDUCE CONTACT SYSTEM ACTIVATION IN AN IN-VITRO CARDIOPULMONARY BYPASS MODEL
Authors: WENDEL HP HELLER W GALLIMORE MJ HOFFMEISTER HE
Citation: Hp. Wendel et al., HEPARIN-COATED OXYGENATORS SIGNIFICANTLY REDUCE CONTACT SYSTEM ACTIVATION IN AN IN-VITRO CARDIOPULMONARY BYPASS MODEL, Blood coagulation & fibrinolysis, 5(5), 1994, pp. 673-678
THE EFFECTS OF APROTININ ON CHROMOGENIC PEPTIDE SUBSTRATE AND OTHER ASSAYS FOR COMPONENTS OF THE COAGULATION, FIBRINOLYSIS AND PLASMA KALLIKREIN SYSTEMS
Authors: WENDEL HP HELLER W GALLIMORE MJ
Citation: Hp. Wendel et al., THE EFFECTS OF APROTININ ON CHROMOGENIC PEPTIDE SUBSTRATE AND OTHER ASSAYS FOR COMPONENTS OF THE COAGULATION, FIBRINOLYSIS AND PLASMA KALLIKREIN SYSTEMS, Fibrinolysis, 8(5), 1994, pp. 304-308
APROTININ IN THERAPEUTIC DOSES INHIBITS CHROMOGENIC PEPTIDE SUBSTRATEASSAYS FOR PROTEIN-C
Authors: WENDEL HP HELLER W GALLIMORE MJ
Citation: Hp. Wendel et al., APROTININ IN THERAPEUTIC DOSES INHIBITS CHROMOGENIC PEPTIDE SUBSTRATEASSAYS FOR PROTEIN-C, Thrombosis research, 74(5), 1994, pp. 543-548
INFLUENCE OF APROTININ ON DIFFERENT ACTIVATORS OF INTRINSIC COAGULATION PATHWAY IN THE PRESENCE OF ANTICOAGULANTS
Authors: WENDEL HP HELLER W GALLIMORE MJ BANTEL H MULLERBEISSENHIRTZ H HOFFMEISTER HE
Citation: Hp. Wendel et al., INFLUENCE OF APROTININ ON DIFFERENT ACTIVATORS OF INTRINSIC COAGULATION PATHWAY IN THE PRESENCE OF ANTICOAGULANTS, Thrombosis and haemostasis, 69(6), 1993, pp. 626-626
INFLUENCE OF HEPARIN, HEPARIN PLUS APROTININ AND HIRUDIN ON CONTACT ACTIVATION IN A CARDIOPULMONARY BYPASS MODEL
Authors: HELLER W GALLIMORE MJ WENDEL HP HOFFMEISTER HE
Citation: W. Heller et al., INFLUENCE OF HEPARIN, HEPARIN PLUS APROTININ AND HIRUDIN ON CONTACT ACTIVATION IN A CARDIOPULMONARY BYPASS MODEL, Thrombosis and haemostasis, 69(6), 1993, pp. 862-862
APROTININ AND ITS EFFECTS ON CHROMOGENIC SUBSTRATE ASSAYS FOR SOME COMPONENTS OF THE PLASMA DEFENSE SYSTEMS
Authors: WENDEL HP GALLIMORE MJ HELLER W
Citation: Hp. Wendel et al., APROTININ AND ITS EFFECTS ON CHROMOGENIC SUBSTRATE ASSAYS FOR SOME COMPONENTS OF THE PLASMA DEFENSE SYSTEMS, Thrombosis and haemostasis, 69(6), 1993, pp. 1270-1270
Risultati: 1-24 |